Healthcare executives weigh the role of psychedelic medicine in healthcare, including business, policy, and clinical adoption considerations

Psychedelic medicine adoption is framed as a healthcare business and governance decision, with healthcare executives assessing where it fits in clinical practice and health systems. The discussion connects psychedelics to organizational and market questions such as how therapies might be integrated into care pathways, what evidence leaders are looking for, and how regulators and payers may respond. The piece also highlights why executive involvement matters for scaling access safely, including attention to oversight, infrastructure, and the practical realities of implementation beyond initial trials.